Potencial antiproliferativo de la mezcla Linagliptin- Rivaroxaban en el cáncer de cuello uterino: conocimientos mecánicos sobre la orientación de la proteína de señal mutante MAPK, RAS quinasa
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Ver abstracta en PubMed
Resumen
Este resumen es generado por máquina.La combinación de linagliptina y rivaroxaban muestra efectos anticancerígenos prometedores contra las células de cáncer cervical, ofreciendo una alternativa más segura al cisplatino. Esta mezcla demuestra una citotoxicidad sinérgica y una orientación selectiva de las vías clave del cáncer.
Área De La Ciencia
- En el campo de la oncología
- Farmacología
- Biología molecular
Sus Antecedentes
- El reposicionamiento de fármacos es una estrategia clave para descubrir nuevos agentes anticancerígenos.
- Este estudio investiga los mecanismos moleculares combinados de los fármacos existentes contra el cáncer.
Objetivo Del Estudio
- Evaluar las propiedades anticancerígenas y los mecanismos moleculares de una mezcla de linagliptina y rivaroxabano.
- Evaluar la eficacia de la mezcla contra las proteínas de señalización MAPK-RAS mutantes.
Principales Métodos
- Utilizó HeLa y líneas celulares adiposas derivadas de humanos (NHF) para evaluaciones anticancerígenas y de seguridad.
- Se han realizado estudios de combinación y índice de selectividad, junto con simulaciones de acoplamiento molecular computacional.
- Se han investigado las afinidades de unión a las proteínas de señalización de la cinasa mutante en la vía MAPK-RAS.
Principales Resultados
- La mezcla de linagliptina y rivaroxaban suprimió significativamente el crecimiento de las células de cáncer cervical más que los fármacos individuales o el cisplatino.
- La mezcla mostró una menor citotoxicidad en las células normales en comparación con el cisplatino, lo que indica una toxicidad selectiva.
- El acoplamiento molecular reveló fuertes interacciones entre linagliptina/ rivaroxaban y las proteínas mutantes de la kinasa P38 MAPK/ RAS.
Conclusiones
- La mezcla de linagliptina y rivaroxaban presenta una alternativa más segura y eficaz para el tratamiento del cáncer de cuello uterino.
- Los perfiles farmacocinéticos y de seguridad establecidos apoyan su potencial aplicación clínica.
Contact us Si estos videos no son relevantes.
Contact us Si estos videos no son relevantes.
Videos de Conceptos Relacionados
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...